Details der Publikation - Efficacy of pamrevlumab, a connective tissue growth factor monoclonal antibody, in patients with SARS-COV-2 infection.

Medienart:	Klinische Studie

Erscheinungsjahr:	2020
Erschienen:	2020

Enthalten in:	WHO International Clinical Trials Registry Platform - (2020) vom: 07. Dez. Zur Gesamtaufnahme - year:2020

Sprache:	Englisch

Links:	Volltext [kostenfrei]

Themen:	610 Medical Condition: Patients with documented SARS-CoV-2 infection;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08] Phase: Phase 2 Recruitment Status: Authorised-recruitment may be ongoing or finished Study Type: Interventional

Anmerkungen:	WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 03-04-2020, Last updated: 2022-11-24

ICTRP ID:	EUCTR2020-001472-14-IT FibroCov-01

Förderinstitution / Projekttitel:

PPN (Katalog-ID):	CTG007114958


LEADER	01000caa a22002652 4500
001	CTG007114958
003	DE-627
005	20230425182335.0
007	cr uuu---uuuuu
008	210507s2020 xx \|\|\|\|\|o 00\| \|\|eng c
035			\|a (DE-627)CTG007114958
035			\|a (UBBS_Klinische_Studien_WHO)EUCTR2020-001472-14-IT
035			\|a (UBBS_Klinische_Studien_WHO)FibroCov-01
040			\|a DE-627 \|b ger \|c DE-627 \|e rakwb
041			\|a eng
245	1	0	\|a Efficacy of pamrevlumab, a connective tissue growth factor monoclonal antibody, in patients with SARS-COV-2 infection. \|b AN OPEN-LABEL, RANDOMIZED, PARALLEL-ARM STUDY INVESTIGATING THE EFFICACYAND SAFETY OF INTRAVENOUS ADMINISTRATION OF PAMREVLUMAB VERSUS STANDARDOF CARE IN PATIENTS WITH SARS-COV-2 INFECTION - FibroCov
264		1	\|c 2020
336			\|a Text \|b txt \|2 rdacontent
337			\|a Computermedien \|b c \|2 rdamedia
338			\|a Online-Ressource \|b cr \|2 rdacarrier
500			\|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 03-04-2020, Last updated: 2022-11-24
650		4	\|a Medical Condition: Patients with documented SARS-CoV-2 infection;Therapeutic area: Diseases [C] - Respiratory Tract Diseases [C08]
650		4	\|a Study Type: Interventional
650		4	\|a Phase: Phase 2
650		4	\|a Recruitment Status: Authorised-recruitment may be ongoing or finished
650		4	\|a 610
773	0	8	\|i Enthalten in \|t WHO International Clinical Trials Registry Platform \|g (2020) vom: 07. Dez.
773	1	8	\|g year:2020 \|g day:07 \|g month:12
856	4	0	\|u https://www.clinicaltrialsregister.eu/ctr-search/search?query=eudract_number:2020-001472-14 \|z kostenfrei \|3 Volltext
912			\|a GBV_CTG
912			\|a SSG-OLC-PHA
951			\|a AR
952			\|j 2020 \|b 07 \|c 12